Search Results - "McEwan, Brigid"

133 CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity by Terrett, Jonathan, Mcewan, Brigid, Hostetter, Daniel, Gamboa, Luis, Kuppuraju, Meghna, Ghonime, Mohammed, Chain, Robert, Padalia, Zinkal, Kalaitzidis, Demetrios

“…BackgroundCD33 is the most consistently expressed antigen in AML, with high levels and homogeneous expression observed in malignant AML cells from most…”
Get full text

Abstract 880: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro by McEwan, Brigid, Kuppuraju, Meghna, Padalia, Zinkal, Terrett, Jonathan, Kalaitzidis, Demetrios

“…Abstract Hematologic malignancies have proven most responsive to CAR-T therapies. However, there is significant variability in the depth and duration of…”
Get full text

Abstract 1428: Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent preclinical activity against AML cells by McEwan, Brigid, Padalia, Zinkal, Porras, Ashley, Sagert, Jason, Terrett, Jonathan A., Ho, Tony, Kalaitzidis, Demetrios

“…Abstract Acute myelogenous leukemia (AML) has a high mortality rate and remains difficult to treat, making new treatment approaches critical. Chimeric antigen…”
Get full text

Abstract 879: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors by Padalia, Zinkal, Dunn, Andrew, Karagiannis, Konstantinos, McEwan, Brigid, Kuppuraju, Meghna, Sagert, Jason, Karnik, Sushant, Dequeant, Mary-Lee, Terrett, Jonathan, Kalaitzidis, Demetrios

“…Abstract Cancer patients that have undergone multiple lines of treatment can have dysfunctional immune systems. In both solid tumors and hematological…”
Get full text

Abstract 1537: CD70 knockout: A novel approach to augment CAR-T cell function by Dequeant, Mary-Lee, Sagert, Jason, Kalaitzidis, Demetri, Yu, Hui, Porras, Ashley, McEwan, Brigid, Padalia, Zinkal, Tetteh, Paul, Nguyen, Thao, Dunn, Andrew, Spencer, Sarah, Lee, Nicolette, Dar, Henia, Henderson, Daniel, Karnik, Sushant, Keerthipati, Pooja, Terrett, Jonathan A.

“…Abstract CD70 and its ligand, CD27, have been described as both activating and suppressing for different cell types including B and T cells. There has been…”
Get full text

A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel by Smith, Emery, Giuliano, Kenneth A, Shumate, Justin, Baillargeon, Pierre, McEwan, Brigid, Cullen, Matthew D, Miller, John P, Drew, Lawrence, Scampavia, Louis, Spicer, Timothy P

“…Cystic fibrosis (CF), an inherited genetic disease, is caused by mutation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which encodes…”
Get more information

Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors by Terrett, Jonathan A., Kalaitzidis, Demetrios, Dequeant, Mary-Lee, Karnik, Sushant, Ghonime, Mohammed, Guo, Changan, Chain, Robert, Heath, Heidi, Jaishankar, Nivedita, Yuen, Rachel, Settipane, Davis, Padalia, Zinkal, Zakas, Lauren, Kuppuraju, Meghna, Tetteh, Paul, Massilamany, Chandirasegaran, McEwan, Brigid, Leary, Glenn, Dar, Henia, Ferulo, Daniel, Allen, Melanie, Tipton, Kimberley, Serwer, Laura, Nguyen, Thao, Butler-Gauthier, Melanie, Sripakdeevong, Parin, Nagar, Shashwat D., Tang, Yin, Chaudhari, Hemangi, Flanagan, Nicole, Huang, Elaine, Phuyal, Shashwant, Koch, Elizabeth, Dunn, Andrew, Sula, Erisa, Waldman, Jacob, Loaiza, Cristian, Zhang, Maria Lei, Thorstensen, Erin, Steiger, Keith, Schum, Katie, Urbaez, Kayla, Benton, Mark, Ma, Anna, Cohen, Sarah, Weaver, Annie, Finch, Christopher, Morrow, Phuong Khanh

“…Abstract Allo CAR T cells represent an “off-the-shelf” treatment option that addresses the unmet need for immediately available, potentially curative…”
Get full text

274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency by Kalaitzidis, Demetrios, Ghonime, Mohammed, Chain, Robert, Jaishankar, Nivedita, Settipane, Davis, Padalia, Zinkal, Zakas, Lauren, Kuppuraju, Meghna, Tetteh, Paul, Dequeant, Mary-Lee, Karnik, Sushant, Massilamany, Chandirasegaran, McEwan, Brigid, Dar, Henia, Allen, Melanie, Serwer, Laura, Nguyen, Thao, Butler-Gauthier, Melanie, Sripakdeevong, Parin, Nagar, Shashwat, Tang, Yin, Flanagan, Nicole, Huang, Elaine, Phuyal, Shashwant, Dunn, Andrew, Koch, Elizabeth, Sula, Erisa, Waldman, Jacob, Zhang, Maria Lei, Loaiza, Cristian, Thorstensen, Erin, Steiger, Keith, Schum, Katie, Urbaez, Kayla, Ma, Anna, Weaver, Annie Yang, Finch, Christopher, Cohen, Sarah, Morrow, PK, Benton, Mark, Terrett, Jonathan

“…BackgroundCTX110, a CD19-directed first-generation CRISPR-edited CAR T cell therapeutic candidate for B-cell lymphoma, has induced clinical responses and…”
Get full text